# Top 10 outcome extracts from Θεραπευτικά_Πρωτόκολλα_ΕΟΠΕ-10η_Έκδοση_cleaned.json

=== Ranked Outcome 1 (Extract #4, Efficacy) — Score: 3 ===
Sep 28
solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 Feb;21(2):271-282. doi:
10.1016/S1470-2045(19)30691-6,PMID: 31838007; PMCID: PMC7461630.
110. Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried
M, Diaz LA Jr et al, Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite
Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin
Oncol. 2020 Jan 1;38(1):1-10. doi: 10.1200/JCO.19.02105. PMID: 31682550; PMCID: PMC8184060.
111. Subbiah V, Wolf J, Konda B, Kang H,

=== Ranked Outcome 2 (Extract #6, Efficacy) — Score: 3 ===
νοθεραπεία.
Σημείωση: O συνδυασμός Doxorubicin και Trabectedin στη θεραπεία πρώτης γραμμής βρέθηκε ότι αυξάνει σημαντικά i. Fulvestrant
ii. Megestrolacetate
iii. Medroxyprogesteroneacetate
iv. GnRHanalogs
Meri
expre
Onco
ic-Bernstam F, Ma
essing solid tumo
ology Annual Mee
akker V, Oaknin A, et al. Efficacy and safety of trastuzu
ors: DESTINYPanTumor02 interim results. Presente
eting; June 2–6, 2023; Chicago, Illinois.
umab deruxtecan in patients with HER2-
ed at the American Society of Clinical του ανθρώπινου θηλώματος (HPV). Ο εμβολιασμός, έναντι υποτύπων του ιού HPV, δεν αναιρεί τις ισχύουσες
Το θε

=== Ranked Outcome 3 (Extract #12, Safety) — Score: 3 ===
ημείωση: O συνδυασμός Doxorubicin και Trabectedin στη θεραπεία πρώτης γραμμής βρέθηκε ότι αυξάνει σημαντικά i. Fulvestrant
ii. Megestrolacetate
iii. Medroxyprogesteroneacetate
iv. GnRHanalogs
Meri
expre
Onco
ic-Bernstam F, Ma
essing solid tumo
ology Annual Mee
akker V, Oaknin A, et al. Efficacy and safety of trastuzu
ors: DESTINYPanTumor02 interim results. Presente
eting; June 2–6, 2023; Chicago, Illinois.
umab deruxtecan in patients with HER2-
ed at the American Society of Clinical του ανθρώπινου θηλώματος (HPV). Ο εμβολιασμός, έναντι υποτύπων του ιού HPV, δεν αναιρεί τις ισχύουσες
Το θεραπευτικό π

=== Ranked Outcome 4 (Extract #1, Outcome) — Score: 2 ===
irgegård G, Gascón P, Ludwig H. Evaluation of anaemia in patients with multiple myeloma and
lymphoma: findings of the European Cander Anaemia Survey. Eur J Haematol 2006;77:378-386.
8.  (last accessed 8 May 2009).
9. Harper P, Littlewood T. Anaemia of cancer: impact on patient fatigue and long-term outcome.
Oncology 2005;69 Suppl 2:2-7.
αρχική εκτίμηση και η περιοδική παρακολούθηση της οστικής μάζας με Dexa scan στην ΟΜΣΣ, το ισχίο (αυχένα
διατροφικών συμπληρωμάτων), είναι τουλάχιστον 1000 mg για άνδρες ηλικίας 19 έως 70 ετών και 1200 mg
ανά ημέρα για άνδρες ηλικίας 71 ετών και άνω και για τις μετεμμ

=== Ranked Outcome 5 (Extract #5, Efficacy) — Score: 2 ===
he Phase II KEYNOTE-158 Study. J Clin
Oncol. 2020 Jan 1;38(1):1-10. doi: 10.1200/JCO.19.02105. PMID: 31682550; PMCID: PMC8184060.
111. Subbiah V, Wolf J, Konda B, Kang H, Spira A, Weiss J, Takeda M, Ohe Y, Khan S, Ohashi K,
Soldatenkova V, Szymczak S, Sullivan L, Wright J, Drilon A. Tumour-agnostic efficacy and safety of
selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours
(LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol. 2022 Oct;23(10):1261-1273. doi: a)
Στάδια IA και ΙΒ σε όγκους χαμηλής διαφοροποίησης (grade 3)
b)
Στάδια ΙC-IV
ΘΕΡΑΠ

=== Ranked Outcome 6 (Extract #7, Efficacy) — Score: 2 ===
–101.
4. Jordan K, Jahn F, Aapro M. Recent developments in the prevention of chemotherapy-induced nausea and
vomiting (CINV): a comprehensive review. Ann Oncol. 2015 Jun;26(6):1081-90.
5. Aapro M, Carides A, Rapoport BL, Schmoll HJ, Zhang L, Warr D. Aprepitant and fosaprepitant: a 10-year
review of efficacy and safety. Oncologist. 20 Apr;20(4):450-458.
6. Antiemesis, NCCN guidelines, version 4.2020 at:
7. SANCUSO περίληψη χαρακτηριστικών προϊόντος
8. Larkin et al, Diagnosis, assessment and management of constipation in advanced cancer ESMO clinical
practice guidelines Annals of Oncology 29 (Supplement

=== Ranked Outcome 7 (Extract #8, Efficacy) — Score: 2 ===
our years of experience,
. 2010 Jun; 56(6): 514–517
4. Khanna I, Pillarisetti S, Buprenorphine – an attractive opioid with underutilized potential in treatment of
chronic pain, Journal of pain research, volume 2015: 8 pages 859-870.
5. Raffa R, Ding Z.,Examination of the preclinical antinociceptive efficacy of buprenorphine and its
designation as full- or partial-agonist, Acute Pain2007;145-152.
6. Pergolizzi J, Aloisi AM, Filitz J, Langford R, Likar R, Mercadante S et al, Current Knowledge of
Buprenorphine and Its Unique Pharmacological Profile, Pain Practice 2010; 10; 428-450.
7. Virk Ms, Arttamangl

=== Ranked Outcome 8 (Extract #9, Efficacy) — Score: 2 ===
insworth JD, Spigel DR, Clark BL, et al. Paclitaxel/carboplatin/etoposide versus
Row 3: gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a Row 1: review of 56 cases. Cancer 1987; 59:572.
Row 2: 44. Mukai H, Katsumata N, Ando M, et al. Safety and efficacy of a combination of docetaxel and cisplatin in
Row 3: patients with unknown primary cancer. Am J Clin Oncol. 2010;33:32–35.
Row 4: 45. Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-
Row 5: fluorouracil with or without docetaxel for larynx pr

=== Ranked Outcome 9 (Extract #10, Efficacy) — Score: 2 ===
n
Row 7: Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical
Row 8: Trial. JAMA 2017; 318:1047.
Row 9: 7. Boettger S, Jenewein J, Breitbart W. Haloperidol, risperidone, olanzapine and aripiprazole in the
Row 10: management of delirium: A comparison of efficacy, safety, and side effects. Palliat Support Care. 2015 Row 1: Νόσημα|Εμπορική ονομασία εμβολίου|Σύσταση|Χρονισμός|Παρατηρήσεις
Row 2: Γρι�πη|Fluarix, Influvac, Vaxigrip Fulcelvax, Fluad, Efluelda|Ετη�σιος εμβολιασμο�ς για ο�λους. Δυνητικα� με “ενισχυμε�νο” εμβο�λιο για τους 65 ετω�ν και α�νω|Αρχε�ς

=== Ranked Outcome 10 (Extract #11, Safety) — Score: 2 ===
EYNOTE-158 Study. J Clin
Oncol. 2020 Jan 1;38(1):1-10. doi: 10.1200/JCO.19.02105. PMID: 31682550; PMCID: PMC8184060.
111. Subbiah V, Wolf J, Konda B, Kang H, Spira A, Weiss J, Takeda M, Ohe Y, Khan S, Ohashi K,
Soldatenkova V, Szymczak S, Sullivan L, Wright J, Drilon A. Tumour-agnostic efficacy and safety of
selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours
(LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol. 2022 Oct;23(10):1261-1273. doi: a)
Στάδια IA και ΙΒ σε όγκους χαμηλής διαφοροποίησης (grade 3)
b)
Στάδια ΙC-IV
ΘΕΡΑΠΕΙΑ ΣΥΝΤΗΡΗ

